Absci Corp (ABSI)vsNovartis AG ADR (NVS)
ABSI
Absci Corp
$6.40
-12.81%
HEALTHCARE · Cap: $1.06B
NVS
Novartis AG ADR
$148.38
-2.52%
HEALTHCARE · Cap: $289.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3081490% more annual revenue ($56.58B vs $1.84M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
ABSI
Avoid20
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABSI.
Margin of Safety
-65.2%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABSI
The strongest argument for ABSI centers on Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ABSI
The primary concerns for ABSI are EPS Growth, Market Cap, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
ABSI profiles as a value stock while NVS is a declining play — different risk/reward profiles.
ABSI carries more volatility with a beta of 2.46 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 20/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Absci Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Absci Corp (ABSI) is an innovative biotechnology firm leveraging an advanced AI-driven platform to transform drug discovery. By enabling the swift generation of high-quality proteins and therapeutic candidates, the company accelerates development timelines and reduces costs, positioning itself as a vital player in the biopharmaceutical landscape. Absci's strategic collaborations with various partners highlight its dedication to creating next-generation therapies, while its expanding pipeline of proprietary programs underscores its potential to drive significant advancements in healthcare and tackle pressing medical challenges.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?